Lineage Cell Therapeutics’ (LCTX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research report released on Tuesday morning,Benzinga reports. They currently have a $2.00 price objective on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Monday. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Lineage Cell Therapeutics has an average rating of “Buy” and a consensus price target of $4.25.

Lineage Cell Therapeutics Stock Performance

Shares of LCTX stock opened at $1.71 on Tuesday. Lineage Cell Therapeutics has a fifty-two week low of $0.37 and a fifty-two week high of $2.09. The stock’s fifty day moving average price is $1.73 and its two-hundred day moving average price is $1.23. The company has a market cap of $390.50 million, a PE ratio of -9.50 and a beta of 1.77.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.11). The business had revenue of $3.68 million for the quarter, compared to the consensus estimate of $2.30 million. Lineage Cell Therapeutics had a negative return on equity of 20.00% and a negative net margin of 374.84%. On average, equities analysts predict that Lineage Cell Therapeutics will post -0.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Lineage Cell Therapeutics

A number of hedge funds have recently modified their holdings of LCTX. Broadwood Capital Inc. increased its holdings in Lineage Cell Therapeutics by 18.9% in the first quarter. Broadwood Capital Inc. now owns 49,560,992 shares of the company’s stock valued at $22,382,000 after purchasing an additional 7,894,737 shares during the period. Comerica Bank lifted its holdings in Lineage Cell Therapeutics by 275.0% during the 1st quarter. Comerica Bank now owns 3,000,000 shares of the company’s stock worth $1,355,000 after buying an additional 2,200,000 shares during the period. Vanguard Group Inc. grew its position in shares of Lineage Cell Therapeutics by 6.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,006,930 shares of the company’s stock valued at $15,222,000 after buying an additional 524,057 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Lineage Cell Therapeutics in the first quarter valued at about $233,000. Finally, Royal Bank of Canada increased its stake in shares of Lineage Cell Therapeutics by 1,578.9% in the first quarter. Royal Bank of Canada now owns 528,656 shares of the company’s stock valued at $237,000 after buying an additional 497,168 shares during the period. Institutional investors and hedge funds own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.